Vifor Fresenius Medical Care Renal Pharma
Clinical trials sponsored by Vifor Fresenius Medical Care Renal Pharma, explained in plain language.
Renal pharmaceutical company, a joint venture of Fresenius Medical Care and Vifor Pharma.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for kidney patients: drug safely lowers dangerous potassium levels
Disease control CompletedThis study tested a drug called patiromer in 262 Chinese adults with chronic kidney disease and high potassium levels. Participants took patiromer for 4 weeks, then some switched to placebo for 8 weeks to see if potassium stayed controlled. The goal was to manage potassium safely…
Phase 3 • Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug may scratch the itch for dialysis patients
Symptom relief CompletedThis study tested a drug called difelikefalin to see if it can reduce moderate-to-severe itching in Chinese adults on hemodialysis. 260 participants received either the drug or a placebo three times a week for 12 weeks. The main goal was to measure changes in itching intensity us…
Phase 3 • Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Symptom relief
Last updated Jun 26, 2026 15:36 UTC